Clinica Privada Velez Sarsfield

Córdoba X5016LIG

2 studies enrolling now · 11 studies all time

What they study most

Antibody-mediated Rejection, Atrial Fibrillation, C3 Glomerulonephritis, C3 Glomerulopathy, C3G, Complement 3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), DDD, Dense Deposit Disease, Diabetes, Type 2, End Stage Kidney Disease

Studies at this site

• A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy — Recruiting now
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Recruiting now
• A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB — Recruiting now
• A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE — Running, not enrolling
• A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) — Running, not enrolling
• A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
• A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) — Running, not enrolling
• A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease — Completed
• Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis — Completed
• A Study of Guselkumab in Participants With Active Lupus Nephritis — Stopped early
• Regimen Optimization Study — Completed